Loading...
XSHE002693
Market cap859mUSD
Jan 10, Last price  
15.20CNY
1D
-5.47%
1Q
-5.24%
Jan 2017
41.00%
IPO
82.64%
Name

Hainan Shuangcheng Pharmaceuticals Co Ltd

Chart & Performance

D1W1MN
XSHE:002693 chart
P/E
—
P/S
26.72
EPS
—
Div Yield, %
0.14%
Shrs. gr., 5y
0.69%
Rev. gr., 5y
-6.90%
Revenues
236m
-14.13%
88,182,963112,877,153133,503,319129,664,062149,604,615161,197,722230,970,366145,135,787246,769,505337,242,775346,648,798269,441,762320,293,514274,754,114235,929,899
Net income
-51m
32,107,07264,229,62270,411,92567,998,62266,771,91958,932,80352,679,05506,314,81309,029,166000-50,741,578
CFO
12m
-53.84%
44,267,38355,329,78066,053,41080,217,90656,433,12551,000,68446,238,56038,646,854046,839,43266,584,747023,553,57325,217,76211,639,461
Dividend
Mar 10, 20150.15 CNY/sh
Earnings
May 22, 2025

Profile

Hainan Shuangcheng Pharmaceuticals Co., Ltd. researches, develops, manufactures, and markets synthesized peptide drugs and active pharmaceutical ingredients worldwide. It offers somatostatin, thymosin, clindamycin hydrochloride, thymopentin, L-carnitine, uranin hydrobromide, inosine, cyclophosphine adenosine, motidine, scopolamine, and sodium ferulate for injections, as well as vitamin B6. The company was founded in 2000 and is based in Haikou, the People's Republic of China.
URL
http://www.shuangchengmed.com/
IPO date
Aug 08, 2012
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
235,930
-14.13%
274,754
-14.22%
Cost of revenue
272,567
240,897
Unusual Expense (Income)
NOPBT
(36,637)
33,857
NOPBT Margin
12.32%
Operating Taxes
(992)
Tax Rate
NOPAT
(35,645)
33,857
Net income
(50,742)
 
Dividends
(8,686)
Dividend yield
0.27%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
205,303
Long-term debt
135,000
Deferred revenue
8,027
7,636
Other long-term liabilities
Net debt
121,613
50,499
Cash flow
Cash from operating activities
11,639
25,218
CAPEX
(49,197)
Cash from investing activities
24,420
Cash from financing activities
(39,466)
44,934
FCF
(21,476)
66,823
Balance
Cash
31,904
146,010
Long term investments
(18,517)
8,794
Excess cash
1,591
141,066
Stockholders' equity
462,889
569,298
Invested Capital
659,082
640,036
ROIC
5.22%
ROCE
4.32%
EV
Common stock shares outstanding
422,846
410,537
Price
7.51
3.30%
7.27
54.03%
Market cap
3,175,577
6.40%
2,984,604
56.13%
EV
3,343,701
3,102,498
EBITDA
17,409
91,394
EV/EBITDA
192.06
33.95
Interest
9,579
11,186
Interest/NOPBT
33.04%